BidaskClub upgraded shares of Cerus (NASDAQ:CERS) from a strong sell rating to a sell rating in a report released on Friday morning.

A number of other research analysts have also weighed in on the stock. Cantor Fitzgerald reissued an overweight rating on shares of Cerus in a research report on Friday. ValuEngine raised shares of Cerus from a strong sell rating to a sell rating in a research report on Thursday. Zacks Investment Research lowered shares of Cerus from a buy rating to a hold rating in a research report on Wednesday. BTIG Research reissued a neutral rating on shares of Cerus in a research report on Friday, December 8th. Finally, Robert W. Baird reissued a buy rating and set a $5.00 price target on shares of Cerus in a research report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $6.17.

Shares of Cerus (NASDAQ:CERS) traded up $0.12 during midday trading on Friday, hitting $3.84. 673,678 shares of the stock were exchanged, compared to its average volume of 587,444. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.71 and a quick ratio of 3.11. Cerus has a 52-week low of $1.93 and a 52-week high of $4.70. The firm has a market capitalization of $452.22, a PE ratio of -6.51 and a beta of 1.93.

Cerus (NASDAQ:CERS) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03. Cerus had a negative net margin of 159.35% and a negative return on equity of 142.18%. The company had revenue of $10.80 million for the quarter, compared to analyst estimates of $11.95 million. During the same period last year, the firm earned ($0.14) earnings per share. The firm’s revenue was up 5.9% on a year-over-year basis. research analysts forecast that Cerus will post -0.57 EPS for the current year.

A number of hedge funds have recently made changes to their positions in the business. Elk Creek Partners LLC raised its position in Cerus by 6.8% in the third quarter. Elk Creek Partners LLC now owns 6,128,026 shares of the biotechnology company’s stock worth $16,730,000 after acquiring an additional 388,741 shares during the period. Vanguard Group Inc. raised its position in Cerus by 3.9% in the second quarter. Vanguard Group Inc. now owns 4,892,503 shares of the biotechnology company’s stock worth $12,281,000 after acquiring an additional 184,076 shares during the period. Senvest Management LLC raised its position in Cerus by 0.7% in the third quarter. Senvest Management LLC now owns 2,960,398 shares of the biotechnology company’s stock worth $8,082,000 after acquiring an additional 20,000 shares during the period. Ark Investment Management LLC raised its position in Cerus by 126.5% in the second quarter. Ark Investment Management LLC now owns 1,680,925 shares of the biotechnology company’s stock worth $4,219,000 after acquiring an additional 938,647 shares during the period. Finally, Northern Trust Corp raised its position in Cerus by 3.2% in the second quarter. Northern Trust Corp now owns 1,269,773 shares of the biotechnology company’s stock worth $3,186,000 after acquiring an additional 39,684 shares during the period. 56.44% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/01/06/cerus-cers-upgraded-to-sell-at-bidaskclub.html.

Cerus Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Analyst Recommendations for Cerus (NASDAQ:CERS)

Receive News & Stock Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related stocks with our FREE daily email newsletter.